Holen Sie sich die Stockscreener-App
4.0021
3.95%
-0.1779
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.18
Offen:
$4.17
24-Stunden-Volumen:
3.69M
Relative Volume:
0.71
Marktkapitalisierung:
$324.83M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.4403
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-8.75%
1M Leistung:
-41.73%
6M Leistung:
-41.47%
1J Leistung:
-46.40%
1-Tages-Spanne:
$3.93
$4.20
1-Wochen-Bereich:
$3.93
$4.35
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.005 | 384.45M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.15 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
548.96 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.86 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
567.95 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.05 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News
Why Altimmune Inc. stock attracts strong analyst attentionHigh Yield Opportunities - beatles.ru
How Altimmune Inc. stock performs during market volatilityTrending Stock Alert - Newser
What makes Altimmune Inc. stock price move sharplyFree Risk Assessment Services - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World
Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World
Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest
The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World
Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks
Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView
Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria
Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada
Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest
Altimmune resumed with a Sell at Goldman Sachs - TipRanks
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks
Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com South Africa
ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
How To Trade (ALT) - news.stocktradersdaily.com
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluati - GuruFocus
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - The Manila Times
Altimmune, Inc. Enrolls First Patient in RESTORE Phase 2 Trial for Pemvidutide in Alcohol-Associated Liver Disease - Quiver Quantitative
Altimmune enrolls first patient in ALD treatment trial - Investing.com
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial - Insider Monkey
ALT ALERT: Levi & Korsinsky Investigates Altimmune, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Sequoia Financial Advisors LLC Decreases Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Altimmune, Inc. (ALT) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, ... - Bluefield Daily Telegraph
Altimmune’s Unexpected Surge: What’s Behind It? - StocksToTrade
Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Value Index - MarketScreener
Altimmune plunges after mid-stage trial data for MASH therapy - MSN
Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief - Benzinga
Altimmune stock rises on positive Phase 2b MASH trial results - Investing.com
Altimmune (ALT) Reports Promising Phase 2b Results for Pemvidutide | ALT Stock News - GuruFocus
Altimmune (ALT) Shares Drop Despite Positive Phase 2b Trial Results | ALT Stock News - GuruFocus
Altimmune (ALT) Reports Promising Phase 2b Trial Results for Pemvidutide | ALT Stock News - GuruFocus
Altimmune stock falls after MASH treatment trial results By Investing.com - Investing.com India
Altimmune's weight-loss drug meets main goal in fatty liver disease trial - TradingView
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 - Yahoo Finance
Altimmune Shares Soar 3.39% on Positive Diabetes Data - AInvest
Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times
Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions - Yahoo Finance
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
3.69%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):